Episode Details

Brazil's ANVISA has opened Public Call No. 4/2026, seeking industry feedback on a major revision of its medical device post-market vigilance (Tecnovigilância) framework. With a specific focus on the challenges posed by Software as a Medical Device (SaMD) and AI, this consultation offers a critical opportunity for manufacturers to influence future regulations. This episode breaks down the scope of the proposed changes, the strategic importance of participating, and the key deadline of mid-October 2026 for submitting feedback. Key Questions: - What is ANVISA's Public Call No. 4/2026 about? - How is Brazil updating its medical device post-market vigilance (Tecnovigilância) framework? - Why are Software as a Medical Device (SaMD) and AI a specific focus of this consultation? - What is the deadline for manufacturers to submit feedback to ANVISA? - Who is most affected by these proposed changes? - What are the key challenges in post-market surveillance for AI-enabled medical devices? - How can manufacturers strategically influence the future of Brazilian medical device regulation? - What practical steps should regulatory teams take right now? Sources: - https://www.smart-mdr.com/anvisa-launches-consultation-on-medical-device-vigilance-framework/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you access global markets faster. Our experts in Brazil can help you understand ANVISA's proposed vigilance changes, assess the impact on your SaMD and AI products, and formulate a strategic response to Public Call No. 4/2026. We act as your local representative, manage technical submissions, and provide continuous regulatory monitoring to ensure you stay compliant. Leverage our expertise to shape regulations and secure your market presence in Brazil. Visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai.